首页> 美国卫生研究院文献>Acta Pharmacologica Sinica >Different network pharmacology mechanisms of Danshen-based Fangjis in the treatment of stable angina
【2h】

Different network pharmacology mechanisms of Danshen-based Fangjis in the treatment of stable angina

机译:丹参方剂治疗稳定型心绞痛的不同网络药理机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Danshen (Salvia miltiorrhiza) preparations such as Danhong injection, Danshen injection, Salvianolate injection, compound Danshen injection and Sodium Tanshinone IIA Sulfonate (STS) injection are widely used in China to treat stable angina (angina pectoris) caused by coronary heart disease. In this study we compared the network pharmacological mechanisms of the 5 Danshen preparations. Following a literature search performed in PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI) database, China Biology Medicine (CBM) database, China Conference Paper Database, Wanfang Database, VIP Database and Conference Proceedings Citation Index (through January 2015), 444 randomized controlled trial publications detailing the use of the 5 Danshen-based injections for treating stable angina were identified, and their combined data were analyzed using a network meta-analysis. All of the 5 Danshen-based preparations were effective in treating stable angina with clinical improvement rates of 72.4%–91.6% and electrocardiogram (ECG) improvement rates of 54.5%–71.6%. According to both clinical improvement and ECG improvement, the 5 Danshen-based preparations were ranked as follows: Danhong injection > Salvianolate injection > STS injection > compound Danshen injection > Danshen injection. There were no significant differences among the safety profiles of the 5 Danshen preparations. The meta-analysis results were further examined using a network pharmacology approach and functional enrichment analysis, which revealed that Danshen and Danhong injections affected 4 and 15 signaling pathways, respectively, and that the 4 signaling pathways affected by Danshen were a subset of those influenced by Danhong. Therefore, Danhong injection affected some unique signaling pathways that might regulate lipoprotein metabolism, oxidation, and inflammation, and protect vascular endothelia, reflecting the multi-component and multi-target characteristics of this traditional formula and its strengths in treating complex diseases.
机译:丹参注射液,丹参注射液,丹参多酚酸盐注射液,复方丹参注射液和丹参酮IIA磺酸钠(STS)注射液等丹参(Salvia miltiorrhiza)制剂在中国被广泛用于治疗由冠心病引起的稳定型心绞痛(心绞痛)。在这项研究中,我们比较了5种丹参制剂的网络药理机制。在PubMed,EMBASE,Cochrane图书馆,中国国家知识基础设施(CNKI)数据库,中国生物医学(CBM)数据库,中国会议论文数据库,万方数据库,VIP数据库和会议论文引用索引中进行了文献检索(截止2015年1月) ,确定了444份随机对照试验出版物,详细介绍了使用5种基于丹参的注射液治疗稳定型心绞痛的情况,并使用网络荟萃分析分析了它们的合并数据。 5种基于丹参的制剂均能有效治疗稳定型心绞痛,临床改善率为72.4%–91.6%,心电图(ECG)改善率为54.5%–71.6%。根据临床改善和心电图改善,以丹参为基础的5种制剂的排名如下:丹红注射液>丹酚酸酯注射液> STS注射液>复方丹参注射液>丹参注射液。 5种丹参制剂的安全性之间没有显着差异。使用网络药理学方法和功能富集分析进一步审查了荟萃分析结果,结果表明丹参和丹红注射液分别影响4和15个信号通路,而丹参影响的4个信号通路是受丹参影响的子集。丹洪因此,丹红注射液影响了一些独特的信号通路,这些通路可能调节脂蛋白的代谢,氧化和炎症,并保护血管内皮,反映出该传统配方的多成分和多靶点特征及其在治疗复杂疾病中的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号